News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Deals Worth $1.75 Billion Offer Insight into Abbott Laboratories (ABT)'s Spinoff Strategy


3/19/2012 8:48:21 AM

Recent acquisitions underscore the Abbott's determination to augment the new firm's drug pipeline ahead of the spin, even if it comes at a hefty price with little guarantee the investments will pay off. Before Abbott Laboratories officially lops off its legacy pharmaceutical business into a separate publicly traded enterprise, it's making an effort to restock the shelves to strengthen the spinoff company's prospects. Since the North Chicago-based medical products giant announced the split in October, it has agreed to spend up to $1.75 billion in two high-profile licensing deals that will give the new firm access to a host of promising drugs.

Read at Chicago Tribune

comments powered by Disqus
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES